Dr. Christopher Ames to Join Aclarion as a Key Opinion Leader Surgeon Advisor

December 22, 2022

https://www.globenewswire.com/news-release/2022/12/22/2578791/0/en/Dr-Christopher-Ames-to-Join-Aclarion-as-a-Key-Opinion-Leader-Surgeon-Advisor.html

Broomfield, CO, Dec. 22, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq:ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Dr. Christopher Ames, Director of Spinal Deformity and Spine Tumor Surgery and Co-Director of the Combined High Risk Spine Service, the Neurospinal Disorders Program, and the UCSF Spine Center at the University of California at San Francisco will advise the company as a Key Opinion Leader (KOL) nationally. 

Read more at globenewswire.com

Related news for (ACON)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.